Global Drug Safety & Pharmacovigilance Certification Program Regulatory Requirements Webinar (ON-DEMAND)
18 sept. 2024 11h13 HE
|
Research and Markets
Dublin, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The "Global Regulatory Requirements for Drug Safety & Pharmacovigilance Certification Program" training has been added to ResearchAndMarkets.com's...
Erythropoietin Drugs Market Estimated to Reach USD 14.3 billion, Advancing at a CAGR of 3.8% by 2034: Transparency Market Research Inc.
18 sept. 2024 07h05 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The global erythropoietin drugs market is estimated to surge at a CAGR of 3.8% from 2024...
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
17 sept. 2024 11h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis &...
PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease
16 sept. 2024 04h00 HE
|
C4X Discovery Holdings PLC
C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses...
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
11 sept. 2024 05h00 HE
|
Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer
10 sept. 2024 07h00 HE
|
Charm Therapeutics
PRESS RELEASE CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer Highly experienced dealmaker to lead CHARM’s business development and drive strategic value from CHARM’s...
Superluminal Medicines Closes $120 Million Series A Round
09 sept. 2024 07h00 HE
|
Superluminal Medicines Inc.
Superluminal Medicines, Inc. announced the closing of a $120 million Series A funding round.
2 Day Virtual Workshop: Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course
06 sept. 2024 06h42 HE
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course 24" conference has been added to ...
Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform™
05 sept. 2024 07h00 HE
|
Leapfrog Bio
Leapfrog Bio today announced a publication in Nature PJ Precision Oncology describing and validating its Precision PGx Platform™
Drug Screening Market Trends and Opportunities Report 2024-2030: Growing Prevalence of Substance Abuse Drives Demand for Comprehensive Drug Screening Solutions
04 sept. 2024 09h55 HE
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Drug Screening - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Drug Screening...